Novavax and Catalent Biologics Enter Strategic Partnership: Allowing Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax’ Manufacturing Assets and Capabilities
- Manufacturing equipment and related assets to be sold to Catalent’s Paragon Gene Therapy for
$18 million in cash - Over 100 manufacturing and quality employees to join
Catalent - Paragon Gene Therapy to take over two clinical development and manufacturing sites in
Gaithersburg, MD - Long-term agreement for Paragon to support
Novavax with product development and manufacturing
This arrangement significantly reduces Novavax’ operating costs and provides a cash payment at closing of approximately
Under the terms of the agreement, Paragon Gene Therapy will purchase from
“This alliance is a true win-win-win for Paragon,
Most
“Novavax’ advanced GMP development and manufacturing capabilities and, even more importantly, its very strong team of experts, will help accelerate our gene therapy manufacturing strategy and rapid growth,” said
“This transaction allows
About
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
About Catalent Biologics
Catalent Biologics has 20+ years’ experience in development, manufacturing, and analytical services for new biological entities, biosimilars, gene therapies and antibody-drug conjugates.
Paragon Gene Therapy, a unit of Catalent Biologics, is an industry leader focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, and oncology immunotherapies. Paragon Gene Therapy has two facilities in
Forward-Looking Statements
Statements herein relating to the future of
Contacts:
Investors
Senior Manager, Investor & Public Relations
ir@novavax.com
240-268-2000
john.woolford@westwicke.com
443-213-0506
Media
BrandZone/ KOGS Communication
kaplan@kogspr.com
781-639-1910
+44 (0)7580 041073
chris.halling@catalent.com
Source: Novavax, Inc.